Fig. 5: Single treatment of empagliflozin is cardioprotective by maintaining mitochondrial ATP levels in hypoxia in mature cardiomyocytes. | Communications Biology

Fig. 5: Single treatment of empagliflozin is cardioprotective by maintaining mitochondrial ATP levels in hypoxia in mature cardiomyocytes.

From: The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice

Fig. 5

a Schematic illustration of the treatment regimen (EMPA empagliflozin). b–g Fluorescence images of cardiomyocytes from each condition (EMPA empagliflozin). Warmer colors indicate higher ATP concentrations. Scale bar: 25 μm. h Time course changes in FRET/GFP ratios in the cardiomyocytes under low- and high-oxygen conditions (db/db [control]: n = 44, db/db [EMPA]: n = 40; 30 min after exposure to low-oxygen conditions: *p = 0.020, 30 min after exposure to high-oxygen conditions: **p = 0.000).

Back to article page